Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The study will assess the efficacy and safety of TYRA-300, an oral, selective FGFR3 inhibitor designed to target the FGFR3 gene mutation commonly seen in NMIBC, while avoiding the toxicities ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...

Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of ...

The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of ...

TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19 + /FGFR4-driven cancers. The US Food and Drug Administration has cleared Tyra's Investigational New Drug application to ...